AMO Pharma is a biopharmaceutical company incorporated in February of 2015. The co-founder, Dr. Michael Snape, has extensive experience in senior scientific and operational roles in both large pharma and biotech companies spanning more than twenty-five years, and has brought together a targeted and experienced senior management team with a proven track record of success in all phases of product development and acquisition. The company is working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options. AMO-02 is an investigational medicine that has not yet been approved for the treatment of patients anywhere in the world. For more information, please visit the AMO Pharma website at http://www.amo-pharma.com/.
Location: United States, North Carolina, Durham
Employees: 11-50
Total raised: $25M
Founded date: 2015
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.09.2015 | - | $25M | - |
Mentions in press and media 2
| Date | Title | Description |
| 17.05.2021 | AMO Pharma Announces Activation of Additional Clinical Trial Sites for Pivotal REACH-CDM Study in Congenital Myotonic Dystrophy | |
| 30.09.2015 | AMO Pharma Raises $25M in Private Equity Financing | AMO Pharma Limited, a London, UK- and Philadelphia, PA-based biopharmaceutical company, raised $25m in private equity financing. Woodford Investment Management made the investment via the Woodford Patient Capital Trust (WPCT). The company i... |